LEO Pharma Announces Health Canada Approval of Anzupgo® for Treatment of Moderate to Severe Chronic Hand Eczema

CNW Group

Tue, Aug 26, 2025, 7:15 AM 9 min read

Anzupgo® (delgocitinib cream 20 mg/g) is the first topical treatment to be specifically indicated for adult patients living with moderate to severe chronic hand eczema (CHE) for whom topical corticosteroids are inadequate or are not advisable.1

• Approval was based on results from the DELTA 1 and 2 trials, which evaluated the safety and efficacy of Anzupgo® compared to cream vehicle.2

• CHE is one of the most common skin disorders of the hands with a global prevalence rate of approximately 4.7 per cent, and an estimated 6 per cent among Canadians.2,3

, /CNW/ - LEO Pharma Inc., Canada is pleased to announce that Health Canada has approved Anzupgo® (delgocitinib cream 20 mg/g) for the treatment of adult (aged ≥18 years) patients with moderate to severe chronic hand eczema (CHE) for whom topical corticosteroids are inadequate or are not advisable. Anzupgo® is the first topical treatment specifically indicated for CHE, one of the most common skin disorders of the hands.3 CHE affects approximately 4.7 per cent of the population globally, and an estimated 6 per cent of Canadians.2,4

The Health Canada approval is based on the results from the DELTA 1 and 2 clinical trials, which included 960 adult patients with moderate to severe CHE (20 per cent of which were Canadian).2,3 Both trials met their primary and key secondary endpoints and showed that Anzupgo cream provided overall superior efficacy versus cream vehicle and was well tolerated over 16 weeks.2

"Living with chronic hand eczema can significantly impact a patient's quality of life, affecting their ability to perform daily activities and their overall well-being," said Dr. Melinda Gooderham, Dermatologist, Medical Director at the SKiN Centre for Dermatology and Principal Investigator for the SKiN Research Centre. "The approval of Anzupgo® provides a new treatment option that targets underlying inflammation and helps manage the symptoms of this debilitating condition."

Anzupgo® is the first topical pan-Janus kinase (JAK) inhibitor to be approved in Canada specifically for moderate to severe CHE. It inhibits the activation of JAK-STAT signaling, which plays a key role in the pathogenesis of CHE.1,5

"Hand eczema can have a profound effect on everyday living and can impact an individual's everyday tasks, family life, ability to work, and mental health," added Executive Director of the Eczema Society of Canada, Amanda Cresswell-Melville. "More treatment options means more hope for those impacted by this challenging condition."